Patent details

Basic Information

Publication number:

EP3576773

PCT Application Number:

US2018016148

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP187473624

PCT Publication Number:

WO2018144542

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

TGF BETA AND ACTRII ANTAGONISTS FOR USE IN TREATING LEUKEMIA

French Title of Invention:

ANTAGONISTES DU TGF BETA ET D'ACTRII À UTILISER DANS LE TRAITEMENT DE LA LEUCÉMIE

German Title of Invention:

TGF-BETA- UND ACTRII-ANTAGONISTEN ZUR BEHANDLUNG VON LEUKÄMIE

SPC Number:

Dates

Filing date:

31/01/2018

Grant date:

18/10/2023

EP Publication Date:

11/12/2019

PCT Publication Date:

09/08/2018

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

18/10/2023

EP B1 Publication Date:

18/10/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

31/01/2024

Expiration date:

31/01/2038

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

11/10/2023

 

 

Name:

Acceleron Pharma Inc.

Address:

128 Sidney Street, Cambridge, MA 02139, United States (US)

Inventor

1

Name:

KUMAR, Ravindra

Address:

United States (US)

2

Name:

PEARSALL, Robert Scott

Address:

United States (US)

Priority

Priority Number:

201762453413 P

Priority Date:

01/02/2017

Priority Country:

United States (US)

Classification

IPC classification:

A61K 38/17; A61K 47/68; A61K 39/395; A61P 35/00; A61P 37/04; A61K 39/00; C07K 14/495; C07K 14/51; C07K 16/22;

Publication

European Patent Bulletin

Issue number:

202342

Publication date:

18/10/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages